Real-world data on the effectiveness, safety and drug survival of dupilumab: an analysis from the TREATgermany registry

Abstract

This interim analysis from the atopic dermatitis registry TREATgermany shows robust long‐term efficacy, favourable safety and high persistence of dupilumab under real life conditions.

Dupilumab but not cyclosporine treatment shifts the microbiome toward a healthy skin flora in patients with moderate‐to‐severe atopic dermatitis

“…[12][13][14][15] The currently most widely used targeted immunomodulating drug for moderate-to-severe AD is the anti-IL-4RA-antibody dupilumab. 16 Multiple studies have shown that dupilumab treatment leads to clinical improvements 17 along with reductions of inflammatory cell infiltrates and proinflammatory cytokine and chemokine expression in lesions 18 and an enhanced skin barrier function with decreased transepidermal water loss (TEWL) and normalized epidermal lipid composition. [19][20][21][22][23][24] Likewise, an increased microbial diversity and decrease of S. aureus abundance during dupilumab treatment was reported.…”

Drug survival analysis of dupilumab and associated predictors in patients with atopic dermatitis in South Korea: single-center, retrospective study

“…An important strength of this study is the long-term follow-up of 4 years, which has not been performed in other studies, to the best of our knowledge [8][9][10][11][12]. Interestingly, the 3-year survival rate (87.6%) and 4year survival rates (87.6%) were the same in this study.…”

“…South Korea has a high hospital density relative to its population, which makes healthcare centers accessible [13]. which may explain the high drug survival rate of dupilumab compared to other reports in Europe and the US [8][9][10][11][12]. Additionally, South Korea's national insurance standards for severe AD are demanding [14].…”

“…Furthermore, little is known about factors associated with the survival of patients with AD. In the United States and Europe, many journals have recently reported on dupilumab drug survival [8][9][10][11][12]. This study provides a comparative survival analysis of two drugs (cyclosporine and dupilumab) approved in South Korea for the treatment of AD and identi es the associated predictors.…”

Prurigo Nodularis: Pathogenesis and the Horizon of Potential Therapeutics

“…Despite these findings, there remains a need for extensive real-world data to comprehensively assess the efficacy and safety of dupilumab in PN. Additionally, novel drugs targeting Th2 polarization in PN have demonstrated encouraging outcomes, such as tralokinumab, an anti-IL-13 monoclonal antibody, which demonstrated a significant reduction in itch severity as early as week 4 in a case series of patients with a PN-like phenotype of AD [45,177]. antibody, which demonstrated a significant reduction in itch severity as early as week 4 in a case series of patients with a PN-like phenotype of AD [45,177].…”